Curosurf and Necrotising enterocolitis neonatal - a phase IV clinical study of FDA data

Summary:

Necrotising enterocolitis neonatal is reported as a side effect among people who take Curosurf (poractant alfa), especially for people who are female, 0-1 old, have been taking the drug for < 1 month also take Aldactone, and have Infection.

The phase IV clinical study analyzes which people have Necrotising enterocolitis neonatal when taking Curosurf. It is created by eHealthMe based on reports of 832 people who have side effects when taking Curosurf from the FDA, and is updated regularly.

What is Curosurf?

Curosurf has active ingredients of poractant alfa. eHealthMe is studying from 832 Curosurf users. Check the latest studies of Curosurf.

What is Necrotising enterocolitis neonatal?

Necrotising enterocolitis neonatal (life threatening infection of intestine in newborn baby) is found to be associated with 31 drugs and 106 conditions by eHealthMe. Check the latest studies of Necrotising enterocolitis neonatal.

On Jul, 26, 2026

832 people reported to have side effects when taking Curosurf.
Among them, 11 people (1.32%) have Necrotising enterocolitis neonatal.

Could Curosurf cause Necrotising enterocolitis neonatal?

Among these 11 people:

How long have people been on Curosurf when they have Necrotising enterocolitis neonatal? *

What is the gender of people who have Necrotising enterocolitis neonatal when taking Curosurf? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Necrotising enterocolitis neonatal when taking Curosurf? *

What are other drugs people take besides Curosurf? *

What are other side effects people have besides Necrotising enterocolitis neonatal? *

Intraventricular Haemorrhage Neonatal (intraventricular bleeding in newborn): 2 people, 18.18%
Bronchopulmonary Dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type): 2 people, 18.18%
Infantile Apnoeic Attack (episodes where breathing stops temporarily in infant): 1 person, 9.09%
Anaemia Neonatal: 1 person, 9.09%
Drug Exposure During Pregnancy: 1 person, 9.09%
Fungal Sepsis (whole body infection by fungus): 1 person, 9.09%
Gastrointestinal Hypomotility (less activity of the intestinal tract): 1 person, 9.09%
Hyperglycemia (high blood sugar): 1 person, 9.09%
Ileal Perforation: 1 person, 9.09%
Thrombocytopenia Neonatal (decrease of platelets in blood in baby less than a month): 1 person, 9.09%

What are the existing conditions these people have? *

Staphylococcal Sepsis (blood infection by an infection with staphylococcus bacteria): 5 people, 45.45%
Infection: 5 people, 45.45%
Respiratory Distress Syndrome (Rds) In Infants (respiratory disease of newborn babies, especially premature babies, characterized by distressful breathing, cyanosis, and the formation of a glassy membrane over the alveoli of the lungs): 4 people, 36.36%
Hypovolaemia (a decreased volume of circulating blood in the body): 2 people, 18.18%
High Blood Pressure: 2 people, 18.18%
Pathogen Resistance: 1 person, 9.09%
Drug Exposure During Pregnancy: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Curosurf and have Necrotising enterocolitis neonatal?

- Check whether Necrotising enterocolitis neonatal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Curosurf:

Curosurf (832 reports)

Browse all side effects of Curosurf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Necrotising enterocolitis neonatal:

Necrotising enterocolitis neonatal (31 drugs)

Browse all the conditions that are associated with Necrotising enterocolitis neonatal:

Necrotising enterocolitis neonatal (106 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on poractant alfa (the active ingredients of Curosurf) and Curosurf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.